Leading Obstetrics Journal Recommends Increased Drugs for Pregnant Women While Failing to Disclose Big Pharma Sponsors

The inordinate undisclosed influence brought to bear by drug companies on medical practice is undermining the credibility of recommended medical practice. Case in point: new recommendations for the treatment of pregnant women would increase their ingestion of powerful drugs. Despite lack of adequate evidence of safety from serious risks of harm, the influential National Partnership for Maternal Safety, is promoting expanded indications for initiating treatment for depression and the prevention of thromboembolism (among other conditions) in pregnant women. The Partnership for Maternal Safety published seven articles in one of the leading obstetrics journals, The Green Journal, which is the official journal of the American College of Obstetricians and Gynecologists. One pesky detail missing from those articles is full disclosure of the significant financial conflicts of interest with 13 drug manufacturers whose disclosure might lead readers to suspect the justification for those radical treatment recommendations by the Partnership for Maternal Safety.